Presenter Disclosure Information

Lee Ellis, MD, FASCO: Data Monitoring Committee for Roche.

Ignacio Wistuba, MD: Consultant for Genentech/Roche, BMS, AZ/MedImmune, Pfizer, HTG Molecular, Asuragen, Merck, GSK and MSD; Speaker’s Bureau for MSD, Genentech/Roche and Pfizer; Research Grant from Genentech, HTG Molecular, DepArray, Merck, BMS, 4D, J&J, Bayer, Karus, MedImmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda and Amgen

Peter O’Dwyer, MD: Consultant for Celgene, Genentech and Array; Research Grant from Pfizer, Genentech, BMS, GSK, Five Prime, FortySeven, BBI, Novartis, Celgene, Incyte, Lilly/Imclone, Array, and H3 Biomedicine, and Taiho; Expert testimony for Bayer and Lilly

Alan Ashworth, PhD, FRS: Consultant for AtlasMDX, Pfizer, Sun Pharma, Bluestar, Gladiator, Genentech, Prolynx, and Tango; Research Grant from Sun Pharma and AZ; Stock Shareholder in Syncona and Tango; Co-Founder of Tango; Patents held jointly with AZ
SWOG Plenary I
Translational Medicine

Science as the Foundation for Rapid and Meaningful Advances in Oncology

Lee M. Ellis, MD
SWOG Vice Chair, Translational Medicine
Departments of Surgical Oncology and Molecular & Cellular Oncology
UT MD Anderson Cancer Center

Thanks to James Rae, PhD (AKA J.R.)
SWOG Executive Officer, Translational Medicine
Quick Overview of Translational Medicine at SWOG

• The vast majority of work is done within each committee: thanks to all for your commitment and expertise
• Recent activities

Thanks to the NCI, the Hope Foundation, and ITSC Partners for support on innumerable initiatives!

– 15 SWOG members attended

• Funding opportunities and recipients
• Brief update on NCTN-CCSC
• TM Chair dinner this evening to discuss TM issues and educational / resource needs
2019 Integrated Translational Science Center Pilot Grants

Identification of a transcriptomic signature associated with response to T/HCQ in pancreatic cancer organoids

Conan Kinsey, MD, PhD, Huntsman Cancer Institute, University of Utah
Dennis Plenker, PhD, Cold Spring Harbor Laboratory

Development and Validation of a Highly Multiplexed Immunohistochemistry Panel for Use as a Risk Stratification Tool for High-Risk Non-Muscle Invasive Bladder Cancer

Joshua Meeks, MD, PhD, Northwestern University Feinberg School of Medicine
Paul Robson, PhD, The Jackson Laboratory for Genomic Medicine

Biomarker discovery for head & neck cancer using scRNA-seq

Paul Swiecicki, MD, University of Michigan Rogel Cancer Center
Michael Samuels, PhD, The Jackson Laboratory for Genomic Medicine

THE HOPE FOUNDATION FOR CANCER RESEARCH

#SupportingSWOG
Integrated Translational Science Center (ITSC)

• Great work done over the last 5 years in collaboration with CSHLs and JAX laboratories
  – Workshops
  – Joint collaborative pilot projects with SWOG and ITSC partners
  – Grant renewal was not funded
  – We are working on alternative plans to continue to partner with outstanding basic science institutes
Upcoming Application Deadlines
All program information available at thehopefoundation.org/research-funding

• Virtual Grant Writing Workshop (pan-NCTN): May 1
• SWOG Young Investigator Training Course: June 21
• Impact Award Grants: July 1 (LOI) / September 1 (full application)
• SWOG Early Exploration and Development (SEED) Fund Grants: July 1

THE HOPE FOUNDATION
FOR CANCER RESEARCH
#SupportingSWOG
SWOG/Hope Foundation Impact Awards

Targeting TP53 with Radioimmunotherapy in Lymphoma
Richard Burack, MD, PhD, University of Rochester Medical Center

Derivation of endocrine and chemotherapy resistance gene signatures and evaluation of previously developed molecular signatures as prognostic and predictive biomarkers in SWOG 8814
Corey Speers, MD, PhD, University of Michigan
James Rae, PhD, University of Michigan

#SupportingSWOG
NCTN-Core Correlatives Scientific Committee (NCTN-CCSC)

• 102 submissions to the NCTN-CCSC to date
  -Some triaged by CTEP
  -Some still under review

• ~60 proposals reviewed by the Committees through April
  33 approvals
  20 disapprovals

  3 proposals currently out for revisions
  4 proposals received revisions decisions but were withdrawn/never resubmitted
Plenary 1: Translational Medicine

3:40 - 4:05 pm  The NCI CIMAC-CIDC Immune Profiling Network: Opportunities for SWOG Investigators
   - Ignacio I. Wistuba, M.D., MDACC

4:05 - 4:30 pm  The Evolution of NCI-MATCH: What's Next for SWOG and the NCTN
   - Peter J. O'Dwyer, M.D., U Penn, ECOG-ACRIN

4:30 - 4:55 pm  DNA Repair and Targeted Therapies
   - Alan Ashworth, Ph.D., F.R.S., UCSF